Castration-Resistant Prostate Cancer Bone Metastasis Response Measured by 18F-Fluoride PET After Treatment with Dasatinib and Correlation with Progression-Free Survival: Results from American College of Radiology Imaging Network 6687
| Autor: | Ben Herman, Celestia S. Higano, Fenghai Duan, Bennett B. Chin, Donna Hartfeil, P. G. Febbo, Robert K. Doot, David A. Mankoff, Mark Muzi, Mary-Ellen Taplin, Evan Y. Yu, Jina M. Taub, Xuan Deng, Joshi J. Alumkal |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Oncology
Male medicine.medical_specialty Pathology Fluorine Radioisotopes Biopsy Dasatinib Standardized uptake value Antineoplastic Agents Bone Neoplasms Article Bone and Bones Disease-Free Survival Bone remodeling Prostate cancer Internal medicine hemic and lymphatic diseases medicine Clinical endpoint Biomarkers Tumor Image Processing Computer-Assisted Humans Radiology Nuclear Medicine and imaging Progression-free survival Neoplasm Metastasis Protein Kinase Inhibitors Aged Aged 80 and over business.industry Bone metastasis Middle Aged medicine.disease Prostatic Neoplasms Castration-Resistant Thiazoles Pyrimidines Treatment Outcome Receptors Androgen Pharmacodynamics Positron-Emission Tomography business Tomography X-Ray Computed medicine.drug |
| ISSN: | 0091-8385 |
| Popis: | (18)F-fluoride PET quantitatively images bone metabolism and may serve as a pharmacodynamic assessment for systemic therapy such as dasatinib, a potent SRC kinase inhibitor, with activity in bone.This was an imaging companion trial (American College of Radiology Imaging Network [ACRIN] 6687) to a multicenter metastatic castration-resistant prostate cancer (CRPC) tissue biomarker-guided therapeutic trial (NCT00918385). Men with bone metastatic CRPC underwent (18)F-fluoride PET before and 12 weeks after initiation of dasatinib (100 mg daily). Dynamic imaging was performed over a 15-cm field of view for trial assessments. The primary endpoint was to determine whether changes in (18)F-fluoride incorporation in tumor and normal bone occurred in response to dasatinib. Other endpoints included differential effect of dasatinib between (18)F-fluoride incorporation in tumor and normal bone, (18)F-fluoride transport in bone metastases, correlation with progression-free survival (PFS), prostate-specific antigen, and markers of bone turnover.Eighteen participants enrolled, and 17 underwent interpretable baseline (18)F-fluoride PET imaging before initiation of dasatinib. Twelve of 17 patients underwent on-treatment PET imaging. Statistically significant changes in response to dasatinib were identified by the SUVmaxavg (average of maximum standardized uptake value [SUVmax] for up to 5 tumors within the dynamic field of view) in bone metastases (P = 0.0002), with a significant differential (18)F-fluoride PET response between tumor and normal bone (P0.0001). Changes in (18)F-fluoride incorporation in bone metastases had borderline correlation with PFS by SUVmaxavg (hazard ratio, 0.91; 95% confidence interval, 0.82-1.00; P = 0.056). Changes by SUVmaxavg correlated with bone alkaline phosphatase (P = 0.0014) but not prostate-specific antigen (P = 0.47).This trial provides evidence of the ability (18)F-fluoride PET to delineate treatment response of dasatinib in CRPC bone metastases with borderline correlation with PFS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|